SRTS

Sensus Healthcare, Inc. Common Stock

SRTS
Closed
$2.92
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 60 full-time employees. The company went IPO on 2016-06-03. The firm is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The firm uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters.
Country

US

CEO

Mr. Joseph Sardano

IPO date

2016

Employees

60

ISIN

US81728J1097

Key stats

Open

$2.95

Volume

18.69K

Market cap

$48.73M

Prev. close

$2.92

Impl / hst vl

-

Open interest

$0.00

$2.92

Day’s Range

$3.06

$2.66

52W Range

$5.49

Valuation

61
Valuation score
Undervalued
P/E
-
P/S
2.17
P/B
1.08
Current ratio
7.27
Debt / Equity
-0.40
ROE
-15.79%
Gross margin
29.20%
Income growth
-17.08%
FCF growth
58.82

Analysts estimates

Consensus rating
Buy

The average rating from top 7 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$5.87
The top 6 analysts forecasts that 12-month price may increase by 100.86%, with a low of $4.55 and a high of $6.83
$4.55
Low
$5.87
Avg
$6.83
High
Current price

Earnings

Q1 ‘26 revenue
$3.39M
Q1 ‘26 net income
-$2.63M
Revenue
Net income
Previous EPS
-$0.16
Estimate EPS
-$0.12
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply